Clinical Implications of Midventricular Obstruction in Patients With Hypertrophic Cardiomyopathy  by Minami, Yuichiro et al.
Journal of the American College of Cardiology Vol. 57, No. 23, 2011
© 2011 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00Cardiomyopathy
Clinical Implications of Midventricular Obstruction
in Patients With Hypertrophic Cardiomyopathy
Yuichiro Minami, MD, Katsuya Kajimoto, MD, Yutaka Terajima, MD, Bun Yashiro, MD,
Dai Okayama, MD, Shintaro Haruki, MD, Takatomo Nakajima, MD, Naomi Kawashiro, MD,
Masatoshi Kawana, MD, Nobuhisa Hagiwara, MD
Tokyo, Japan
Objectives We investigated the prevalence, clinical characteristics, and prognosis of hypertrophic cardiomyopathy (HCM)
patients with midventricular obstruction (MVO).
Background Previous descriptions of patients with MVO have been confined to case reports or small patient series, and this
subgroup of HCM patients has therefore remained underrecognized.
Methods The study population included 490 HCM patients. Left ventricular MVO was diagnosed when the peak midcavi-
tary gradient was estimated to be 30 mm Hg.
Results MVO was identified in 46 patients (9.4%). Patients with MVO were more likely to be symptomatic than those
without. MVO was found to be an independent determinant of HCM-related death in multivariate models (hazard
ratio [HR]: 2.23, p  0.016), and this trend was especially pronounced for the combined endpoint of sudden
death and potentially lethal arrhythmic events (HR: 3.19, p  0.001). Apical aneurysm formation was identified
in 28.3% of patients with MVO and strongly predicted HCM-related death (HR: 3.47, p  0.008) and the com-
bined endpoint of sudden death and potentially lethal arrhythmic events (HR: 5.08, p  0.001). In addition, MVO
without apical aneurysm was also identified as an independent determinant of the combined endpoint of sud-
den death and potentially lethal arrhythmic events (HR: 2.43, p  0.045).
Conclusions This analysis identified MVO as an independent predictor of adverse outcomes, especially the combined end-
point of sudden death and potentially lethal arrhythmic events. Our results suggest that longer periods of expo-
sure to MVO might lead to unfavorable consequences. They also support the principle that the presence of MVO
in patients with HCM has important pathophysiological implications. (J Am Coll Cardiol 2011;57:2346–55)
© 2011 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.033Hypertrophic cardiomyopathy (HCM) is a genetic cardiac
disease characterized by marked variability in morphological
expression and natural history (1). Left ventricular intracav-
itary obstruction is an important pathophysiological com-
ponent of HCM and classically occurs at the subaortic level,
mainly due to systolic anterior motion (SAM) of the
anterior mitral valve leaflet (1). This subaortic obstruction,
called left ventricular outflow tract obstruction (OTO),
occurs at rest in approximately 25% of patients with HCM
and is an independent predictor of adverse clinical conse-
quences (2,3). In a minority of HCM patients, however, the
impedance to flow occurs at the midcavitary level, unrelated
to SAM, and is predominantly caused by marked septal
hypertrophy coming in contact with a hypercontractile left
From the Department of Cardiology, Tokyo Women’s Medical University, Tokyo,
Japan. The authors have reported that they have no relationships to disclose.Manuscript received September 16, 2010; revised manuscript received February 3,
2011; accepted February 8, 2011.ventricular free wall, often with the interposition of the
hypertrophied papillary muscle (4). Previous descriptions of
these patients with midventricular obstruction (MVO) have
been confined to case reports or small patient series because
of the relative rarity and unique pathophysiology of the
condition (5–13). Consequently, this subgroup of patients
with HCM has remained underappreciated, and the clinical
profiles of patients with MVO are largely undefined. This
study was therefore undertaken to investigate the preva-
lence, clinical characteristics, and long-term prognosis of
HCM patients with MVO.
Methods
Patients. The study population included 490 patients with
clinically diagnosed HCM who were enrolled and evaluated
from 1980 to 2005 at Tokyo Women’s Medical University
Hospital, Tokyo, Japan. The initial evaluation was the first
clinical assessment during which an echocardiogram diagnostic
of HCM was obtained, and the most recent evaluation was
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June 7, 2011:2346–55 Midventricular Obstruction in HCMperformed in the clinic or by telephone interview. The study
was performed according to the principles of the Declaration of
Helsinki, and the study protocol was approved by the institu-
tional ethics committee.
HCM. The diagnosis of HCM was based on the identifi-
cation by 2-dimensional echocardiography of a hypertro-
phied, nondilated left ventricle in the absence of any other
cardiac or systemic disease capable of producing a similar
degree of hypertrophy (1).
OTO and MVO. Left ventricular OTO, caused by SAM
of the anterior mitral valve leaflet, was considered to be
present when the estimated peak instantaneous gradient was
30 mm Hg (3,14). Left ventricular MVO was diagnosed
when both of the following criteria were satisfied: 1) the
peak instantaneous midventricular gradient was estimated to
be 30 mm Hg; and 2) midventricular obliteration was
caused by marked septal hypertrophy resulting in contact
with a hypercontractile left ventricular free wall rather than
by SAM of the anterior mitral valve leaflet (6). Patients with
both OTO (SAM) and MVO were excluded from the
MVO group and included in the OTO group (6). This
accounted for 6 of the 110 OTO patients (5.5%) in the
current study.
Apical hypertrophy and aneurysm. The diagnostic criteria
for apical hypertrophy included asymmetrical left ventricular
hypertrophy, confined predominantly to the left ventricular
apex, with an apical wall thickness 15 mm (15). A left
ventricular apical aneurysm was defined as a discrete, thin-
walled dyskinetic or akinetic segment of the most distal
portion of the chamber with a relatively wide communica-
tion to the left ventricular cavity (16).
Arrhythmias. Documentation of atrial fibrillation was
based on electrocardiographic recordings obtained either
after acute onset of symptoms or fortuitously during routine
medical examinations in asymptomatic patients. Ambula-
tory electrocardiograms covering at least a 24-h period were
reviewed in all patients for the occurrence of nonsustained
ventricular tachycardia, defined as a minimum of 3 consec-
utive ventricular beats with a rate of 120 beats/min (1).
Mode of death. Three modes of HCM-related death were
defined for the purposes of survival analysis (1): 1) a
combined endpoint of sudden death and potentially lethal
arrhythmic events, in which unexpected death occurred in
the absence of or1 h from symptom onset in patients who
had previously experienced a relatively stable or uneventful
course, including resuscitated cardiac arrest and appropriate
implantable defibrillator interventions; 2) heart failure–
related death in the context of progressive cardiac decom-
pensation 1 year before death, particularly if complicated
by pulmonary edema or evolution to end-stage phase; and
3) stroke-related death, which occurred in patients who died
as a result of ischemic stroke.
Echocardiography. Echocardiographic studies were per-
formed using commercially available ultrasound equipment.
Complete M-mode, 2-dimensional, and Doppler studies
were performed with the patient in the left lateral decubitus ior supine position, using stan-
dard parasternal, apical, and sub-
costal approaches. Color Dopp-
ler imaging and pulse-wave
Doppler echocardiography were
used to localize the site of ob-
struction. Peak left ventricular
intracavitary gradient was quan-
tified using continuous-wave
Doppler echocardiography under
resting conditions. MVO was
defined by systolic apposition of
the mid-left ventricular walls,
and often the papillary muscles,
with abnormally high velocities
persisting through late systole
and often with early diastolic paradoxical jet flow (13).
Contrast-enhanced echocardiography was performed by
manual intravenous injection of 300 mg/ml galactose-
palmitic acid (Levovist, Schering, Berlin, Germany) at a rate
of 5 ml/5 s.
Cardiovascular magnetic resonance (CMR) imaging.
Studies were performed using a Magnetom Vision 1.5-T
whole-body imaging system (Siemens Medical Systems,
Erlangen, Germany [used from 2001 to July 2003]), or a
Gyroscan Intera (Philips Medical Systems, Best, the Neth-
erlands [used from July 2003 to 2005]). Breath-hold
electrocardiography-gated cine steady-state free precession
images were acquired in 7 to 10 short-axis slices and
standard 2- and 4-chamber long-axis orientations. A de-
layed enhancement protocol was used 10 min after intrave-
nous administration of 0.10 to 0.15 mmol/kg gadolinium-
diethylenetriaminepentaacetic acid (Magnevist, Schering)
with a breath-held segmented inversion-recovery sequence
(inversion time, 230 to 300 ms, adjusted by a look-locker
sequence) acquired in the same views as the cine images.
Statistical analysis. Analyses were performed using SAS
system software, version 9.1 (SAS Institute, Cary, North
Carolina). Data were presented as mean  SD and frequen-
cies. Student t tests were used to compare values between the
groups for continuous variables, and Mann-Whitney U tests
ere used for ordinal variables. Normality of distribution was
ssessed using the Kolmogorov-Smirnov test, and equality of
ariances was checked using the F statistic. A chi-square or
isher exact test (when an expected value was5) was used to
ompare nominally scaled variables. Event-free curves were
stimated using the Kaplan-Meier method, and differences
etween curves were assessed by log-rank tests. Univariate and
ultivariate Cox proportional hazards models were applied to
valuate the influence of MVO and MVO with or without
pical aneurysm on HCM-related death and the combined
ndpoint of sudden death and potentially lethal arrhythmic
vents. The proportional hazards assumption was confirmed by
he log (log survival function). The influences of profile,
Abbreviations
and Acronyms
CI  confidence interval
CMR  cardiovascular
magnetic resonance
HCM  hypertrophic
cardiomyopathy
HR  hazard ratio
MVO  midventricular
obstruction
OTO  outflow tract
obstruction
SAM  systolic anterior
motionnteraction, and collinearity in the models were examined using
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Midventricular Obstruction in HCM June 7, 2011:2346–55regression diagnostic analysis. A 2-tailed p value 0.05 was
onsidered to indicate a statistically significant difference.
esults
revalence and baseline characteristics. MVO was iden-
ified in 46 of 490 HCM patients (9.4%). The baseline
emographic and clinical characteristics of the HCM pa-
ients with and without MVO are shown in Table 1. The
ean age at diagnosis of the 46 patients with MVO was
3.2  14.7 years (range 19 to 77 years). The New York
eart Association functional class at diagnosis in patients
ith MVO was significantly higher than that in those
ithout MVO. However, there were no statistically signif-
cant differences with respect to sex, age, family history of
udden death, maximal left ventricular wall thickness, or
rrhythmias between patients with and without MVO.
omparison with OTO and treatments. OTO was iden-
tified in 110 of 490 HCM patients (22.4%). The demo-
graphic, clinical, and therapeutic characteristics of the 46
patients with MVO and the 110 patients with OTO are
shown in Table 2. There was a higher proportion of male
patients with MVO than with OTO, and patients with
MVO had a lower left ventricular intracavitary gradient at
diagnosis. Of the 46 patients with MVO, 43 (93.5%) were
treated with negative inotropic agents, such as beta-
blockers, calcium-channel blockers, and/or class I antiar-
rhythmic drugs (mainly disopyramide). Three patients
(6.5%) underwent dual-chamber pacing therapy, and only 1
patient (2.2%) underwent surgery to reduce the gradient
caused by MVO.
Outcomes. Six of the 46 patients with MVO (13.0%)
experienced episodes of progressive heart failure with an
increase to 3 New York Heart Association functional
class, and 5 patients (10.9%) had nonfatal thromboembolic
Baseline Characteristics of HCM Patients WithTable 1 Baseline Characteristics of HCM Pa
Patie
Male 2
Age at diagnosis, yrs 53
Family history of sudden death
Maximal left ventricular wall thickness, mm 19
Apical aneurysm formation 1
Nonsustained ventricular tachycardia 1
Atrial fibrillation 1
Unexplained syncope 1
NYHA functional class at diagnosis
I 1
II 3
III
IV
Progressive heart failure
Stroke
Follow-up duration, yrs 10Values are n (%) or mean  SD.
HCM  hypertrophic cardiomyopathy; MVO  midventricular obstruction; Nstrokes over the mean follow-up period of 10.4  8.2 years.
Eleven patients (23.9%) experienced HCM-related death
including 2 patients with sudden death, 7 patients with
successfully resuscitated cardiac arrest (with documented
ventricular fibrillation [n  5] and with documented ven-
ricular tachycardia with pulseless collapse [n  2]), and 2
atients with appropriate implantable defibrillator interven-
ions. In univariate analysis, patients with MVO had a
ignificantly greater likelihood of HCM-related death than
atients without MVO (log-rank p 0.017) (Fig. 1A). The
robability of the combined endpoint of sudden death and
otentially lethal arrhythmic events among patients with
VO was also significantly higher than that among pa-
ients without MVO (log-rank p  0.001) (Fig. 1B). The
requency of HCM-related death in patients with MVO
as similar to that in patients with OTO (log-rank p 
.451) (Fig. 2A). Conversely, the probability of the com-
ined endpoint of sudden death and potentially lethal
rrhythmic events among patients with MVO was signifi-
antly higher than that among patients with OTO (log-rank
 0.038) (Fig. 2B). In multivariate modeling, entering
VO and established major primary prevention risk factors
or sudden death (family history of sudden death, maximum
eft ventricular wall thickness 30 mm, nonsustained ven-
ricular tachycardia, and unexplained syncope) (1,17), MVO
as identified as an independent determinant of outcome,
ncluding the risk of HCM-related death (adjusted hazard
atio [HR]: 2.23, 95% confidence interval [CI]: 1.16 to
.29; p  0.016) and the combined endpoint of sudden
eath and potentially lethal arrhythmic events (adjusted
R: 3.19, 95% CI: 1.62 to 6.29; p  0.001) (Table 3).
xercise tests were not performed in all HCM patients, and
bnormal exercise blood pressure was therefore excluded
rom the analysis. The sensitivities of MVO for HCM-
ithout MVOs With and Without MVO
th MVO
6)
Patients Without MVO
(n  444) p Value
.9) 288 (64.9) 0.590
4.7 50.4 14.9 0.232
.0) 55 (12.4) 0.898
.3 19.7 4.2 0.345
.3) 8 (1.8) 0.001
.4) 182 (41.0) 0.164
.9) 140 (31.5) 0.287
.1) 80 (18.0) 0.182
0.004
.3) 247 (55.6)
.4) 159 (35.8)
) 35 (7.9)
) 3 (0.7)
.0) 53 (11.9) 0.826
.9) 56 (12.6) 0.733
.2 11.7 7.3 0.266and Wtient
nts Wi
(n  4
8 (60
.2 1
6 (13
.1 4
3 (28
4 (30
1 (23
2 (26
3 (28
1 (67
2 (4.3
0 (0.0
6 (13
5 (10
.4 8YHA  New York Heart Association.
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potentially lethal arrhythmic events were 17.2%/22.9%,
respectively, and the corresponding specificities were 91.8%/
92.1%, respectively.
Demographic, Clinical, and Therapeutic Charactof HCM Patients With MVO and With OTOTable 2 Demogr phic, Cli ical, and T er peof HCM Patients With MVO and Wi
Pat
Male
Age at diagnosis, yrs
Family history of sudden death
Maximum left ventricular wall thickness, mm
Apical aneurysm formation
Nonsustained ventricular tachycardia
Atrial fibrillation
Unexplained syncope
NYHA functional class at diagnosis
I
II
III
IV
Progressive heart failure
Stroke
Pressure gradient at diagnosis, mm Hg
Treatments
Beta-blockers
Calcium-channel blockers
Class I antiarrhythmic drugs
All interventions combined
Warfarin
Follow-up duration, yrs
Values are n (%) or mean  SD.
OTO  outflow tract obstruction; other abbreviations as in Table 1.
Figure 1 Kaplan-Meier Estimates of the Proportions of Patients
in 46 Patients With MVO and 444 Patients Without M
Patients with midventricular obstruction (MVO) had a significantly greater likelihood
the combined endpoint of sudden death and potentially lethal arrhythmic events (BApical hypertrophy and apical aneurysm formation. Left
ventricular apical hypertrophy was identified in 16 of the 46
patients with MVO (34.8%). All the 16 patients exhibited
mid-left ventricular hypertrophy, and none had hypertrophy
csCharacteristics
O
With MVO
46)
Patients With OTO
(n  110) p Value
0.9) 48 (43.6) 0.050
14.7 55.1 15.7 0.483
3.0) 11 (10.0) 0.578
4.3 20.0 4.9 0.239
8.3) 2 (1.8) 0.001
0.4) 36 (32.7) 0.780
3.9) 36 (32.7) 0.274
6.1) 22 (20.0) 0.401
0.927
8.3) 39 (35.5)
7.4) 57 (51.8)
.3) 13 (11.8)
.0) 1 (0.9)
3.0) 14 (12.7) 0.957
0.9) 13 (11.8) 0.866
14.7 81.0 30.1 0.001
6.1) 92 (83.6) 0.269
0.4) 26 (23.6) 0.375
4.8) 69 (62.7) 0.001
.7) 36 (32.7) 0.002
8.3) 35 (31.8) 0.661
8.2 10.0 6.7 0.761
HCM-Related Adverse Events
pertrophic cardiomyopathy (HCM)–related death (A) and
patients without MVO.eristiut c
th OT
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(n 
28 (6
53.2
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Midventricular Obstruction in HCM June 7, 2011:2346–55confined only to the left ventricular apex below the papillary
muscle level. Left ventricular apical aneurysm was identified
in 13 of the 46 patients with MVO (28.3%). Coronary
artery disease was excluded as a cause of apical aneurysm
formation by the absence of significant coronary arterial
narrowing (50% stenosis) in the left anterior descending
artery using conventional coronary angiography (n  10)
nd no history of chest pain, coronary risk factors, or acute
oronary syndrome (n 3, all younger than 60 years of age).
n apical aneurysm was confirmed by CMR in 8 of the 13
atients. All the 8 patients exhibited late gadolinium en-
ancement in the apical aneurysmal wall itself, with exten-
ion into the hypertrophic region of the left ventricle. An
pical aneurysm was confirmed by contrast-enhanced echo-
ardiography in the remaining 5 patients who did not
ndergo CMR. Development of an apical aneurysm from
VO was observed in 6 of 13 aneurysm patients during the
ollow-up period (Figs. 3 and 4). In the remaining 7
atients, an apical aneurysm was observed at the initial
valuation. In 2 of 6 patients in whom an apical aneurysm
eveloped from MVO, CMR was performed both before
nd after aneurysm formation, and these 2 patients already
xhibited late gadolinium enhancement in the apex before
etection of the apical aneurysm formation (Fig. 3C). The
aseline characteristics of the HCM patients with MVO,
ccording to the presence or absence of an apical aneurysm,
re shown in Table 4. The frequency of nonsustained
entricular tachycardia in patients with an aneurysm was
ignificantly higher than in those without an aneurysm. In
ontrast to the situation in patients with MVO, only 2 of
Figure 2 Kaplan-Meier Estimates of the Proportions of Patients
in 46 Patients With MVO and 110 Patients With OTO
There was no statistically significant difference in HCM-related death rate between
patients with MVO had a significantly greater likelihood of the combined endpoint
Abbreviations as in Figure 1.he 110 patients with OTO (1.8%), and only 8 of the 444atients without MVO (1.8%) were complicated by an
pical aneurysm (Tables 1 and 2).
elationship of apical aneurysm formation to outcomes.
hen patients with MVO were divided into those with
n 13) and those without (n 33) an apical aneurysm, 5 of
3 MVO patients with an apical aneurysm (38.5%) experi-
nced HCM-related death, including sudden death (n  1),
esuscitated cardiac arrest (n 3), and appropriate implantable
efibrillator interventions (n  1). One of the 5 patients with
dverse outcomes had no established major primary prevention
isk factors for sudden death. Six of the 33 MVO patients
ithout an apical aneurysm (18.2%) experienced HCM-
elated death. Two of the 6 patients with adverse outcomes had
o established major primary prevention risk factors for sudden
eath. In multivariate models includingMVOwith or without
n apical aneurysm and established major primary prevention
isk factors for sudden death, apical aneurysm formation in
atients with MVO strongly predicted HCM-related death
adjusted HR: 3.47, 95% CI: 1.38 to 8.73; p 0.008) and the
ombined endpoint of sudden death and potentially lethal
rrhythmic events (adjusted HR: 5.08, 95% CI: 1.97 to 13.05; p
0.001).MVOwithout an apical aneurysmwas also identified as
n independent determinant of the combined endpoint of sudden
eath and potentially lethal arrhythmic events (adjustedHR: 2.43,
5% CI: 1.02 to 5.80; p  0.045), but was not identified as an
independent determinant ofHCM-related death overall (adjusted
HR: 1.72, 95% CI: 0.73 to 4.02; p  0.213).
Discussion
In the current single-center patient cohort, MVO was
HCM-Related Adverse Events
nts with MVO and patients with outflow tract obstruction (OTO) (A). However,
den death and potentially lethal arrhythmic events than patients with OTO (B).With
patie
of sudconfirmed in 9.4% of patients with HCM. Although no
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June 7, 2011:2346–55 Midventricular Obstruction in HCMextensive clinical studies have been designed to determine
the true prevalence of MVO in patients with HCM, MVO
with an akinetic apical chamber has been considered to be a
rare form of HCM, occurring in 1% of cases in the
non-Asian population (5). According to a report from the
United States, however, MVO was found in 8 of 62 patients
(12.9%) with a diagnosis of HCM (18). In addition, MVO
was present in 10.9% of patients with HCM in a 5-year
study performed at an echocardiography laboratory in Italy
(19). Furthermore, diastolic paradoxical jet flow across the
obliterated left ventricular apex toward the base, suggestive
of MVO and a discrete apical chamber, was present in 20 of
198 patients (10.1%) with HCM in a previous study (20).
These variations in prevalence could be the result of racial/
ethnic differences, selection bias, underrecognition, misdi-
agnosis, or differences in the definitions of MVO. Despite
being based on a highly selected population of patients with
HCM from a single large tertiary referral center in Japan,
the results of the current study have revealed novel epide-
miological information about MVO in a relatively large
HCM patient cohort.
A left ventricular apical aneurysm was identified in
approximately one-fourth of HCM patients with MVO in
the current study. Numerous previous case reports and
studies have indicated that MVO is associated with an
apical aneurysm in patients with HCM (5,7,8,16). Maron et
al. (16) hypothesized that a left ventricular apical aneurysm
and the associated regional myocardial scarring developed
secondarily to increased left ventricular wall stress as a result
of MVO and elevated intracavitary systolic pressures. In-
creased wall stress imposes an increased pressure load on the
apical myocardium, increasing its oxygen demand, and
impairs coronary flow through extravascular compression of
the coronary artery, leading to chronic myocardial ischemia
and aneurysm formation. The results of the current study, as
well as those of previous studies, suggest the existence of a
close overlap between MVO and an apical aneurysm in
patients with HCM.
The presence of MVO was identified as an independent
determinant of unfavorable outcomes in our analysis. In
addition, apical aneurysm formation in patients with MVO
more strongly predicted HCM-related adverse events. A
recent study demonstrated a largely unfavorable clinical
course in 28 HCM patients with an apical aneurysm.
Twelve of the 28 patients (42.9%) either died of their
disease or survived with severe adverse HCM-related events
(16). Similarly, 5 of 13 patients (38.5%) with MVO and an
apical aneurysm experienced HCM-related death in the
present study. These results suggest that the higher mortal-
ity observed in patients with MVO might be due partly to
aneurysm formation, which may develop secondarily to
increased left ventricular wall stress as a result of MVO.
Furthermore, the scarred rim of the aneurysm and the
associated extensive areas of myocardial fibrosis have been
regarded as arrhythmogenic substrates for the generation of
malignant ventricular tachyarrhythmias (21,22). It is there-Pr
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Midventricular Obstruction in HCM June 7, 2011:2346–55fore not surprising that the majority of reported HCM-
related events in patients with MVO and an apical aneu-
rysm may be caused by ventricular arrhythmias (7,8). These
observations suggest that the treatment of patients with
MVO already complicated by an apical aneurysm should be
modified to include primary prevention of sudden death
with the use of an implanted defibrillator (16). In addition,
MVO without an apical aneurysm was also associated with
the risk of the combined endpoint of sudden death and
potentially lethal arrhythmic events in this study. Further-
more, 2 MVO patients without an apical aneurysm and with
no additional established major primary prevention risk
factors for sudden death experienced adverse events. Addi-
tional clinical studies are needed to clarify whether the
presence of MVO alone justifies the prophylactic use of an
implantable defibrillator.
In this analysis, we also compared patients with MVO
and those with OTO. Intriguingly, we found that the
probability of HCM-related death in patients with MVO
was similar to that in patients with OTO. Furthermore,
the probability of the combined endpoint of sudden death
and potentially lethal arrhythmic events in patients with
MVO was higher than that in patients with OTO. This
suggests that MVO could be as predictive of unfavorable
outcomes as OTO because of increased wall stress, apical
aneurysm formation, apical myocardial infarction, and
myocardial scarring (16,21,22). Timely recognition of
Figure 3 CMR Images From an HCM Patient in Whom an Apica
Left ventricular long-axis 2-chamber cardiovascular magnetic resonance (CMR) cine
MVO (*). Identical imaging view in the same patient with gadolinium-diethylenetria
(thin arrow, C). After 4 years, 2-chamber long-axis CMR images in end-diastole (D
was associated with regional transmural late gadolinium enhancement of the aneu
as in Figure 1.MVO might thus affect clinical practice decisions byprompting consideration of gradient and wall stress relief
with negative inotropic agents and/or therapeutic inter-
ventions. Numerous previous studies have demonstrated
a reduction in intracavitary pressure gradients in HCM
patients with MVO after dual-chamber pacing and my-
ectomy (9–13). Successful surgical septal myectomy in
OTO patients can completely abolish the gradients,
leading to marked improvement of symptoms and out-
comes (23). Surgical relief of MVO by extensive mid-left
ventricular resection may thus similarly reduce HCM-
related adverse events. However, patients with MVO had
a lower left ventricular intracavitary gradient than those
with OTO in our study cohort. In addition, MVO
patients with an apical aneurysm had slightly lower
midcavitary gradient than those without. This may be
due partly to apical systolic dysfunction (hypokinesia,
akinesia, or dyskinesia) and the midsystolic decrease in
flow that can occur in patients with MVO (13,24). Lower
gradients might lead to underestimation of the prognostic
significance of MVO, resulting in inadequate medication
and/or therapeutic interventions for the gradients of
MVO. In comparison with OTO, MVO patients in this
study used class I antiarrhythmic drugs less and had fewer
invasive procedures to reduce the gradient of MVO,
despite poor outcomes in the MVO patient group.
Further studies are required to evaluate the actual severity of
MVO and to determine the most appropriate treatment
urysm Developed From MVO
es in end-diastole (A) and end-systole (B) from a 67-year-old HCM patient with
entaacetic acid already showing late gadolinium enhancement in the apex
end-systole (E) demonstrating apical aneurysm formation (thick arrow), which
l wall (thin arrow, F). LA  left atrium; LV  left ventricle; other abbreviationsl Ane
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minep
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June 7, 2011:2346–55 Midventricular Obstruction in HCMStudy limitations. The present study was based on the
etrospective enrollment of individual patients with
CM, which is an unavoidable limitation shared by
irtually all large-scale clinical studies on HCM. This
tudy was evaluated in a single tertiary referral center in
apan and was therefore subject to selection bias by
ncluding a highly selected population of patients with
CM. In addition, some HCM patients were taking
edication before their referral to our center, and the
nitial echocardiographic studies in some patients were
hus performed while they were taking medication. Our
esults were thus likely to underestimate the prevalence
nd severity of MVO and OTO in this HCM patient
ohort. The detection of apical hypertrophy and aneu-
ysms in this study was based partly on transthoracic
chocardiography, which has proven to be less reliable for
etecting apical hypertrophy and aneurysms compared
Figure 4 Echocardiographic Images of an HCM Patient in Whom
Left ventricular apical 4-chamber views in end-diastole (A) and end-systole (B) in
diastole (C) and end-systole (D) showing no systolic pooling of contrast agent. Fo
(*) after 4 years demonstrating apical aneurysm formation (thin arrows). Contras
systolic pooling of contrast agent (thick arrow). Abbreviations as in Figures 1 andith the higher spatial resolution and detection capabilityof CMR imaging. In addition to CMR, contrast-
enhanced echocardiography allows better delineation of
the apical endocardium when apical acoustic windows are
difficult to obtain (25). However, CMR and contrast-
enhanced echocardiography were not performed in all
MVO cases in this study, and our data were therefore
likely to underestimate the true prevalence of apical
hypertrophy and aneurysms in this cohort of patients
with MVO.
Conclusions
In this HCM patient cohort, MVO was identified as an
independent determinant of HCM-related death, espe-
cially the combined endpoint of sudden death and po-
tentially lethal arrhythmic events. In addition, apical
Apical Aneurysm Developed From MVO
ar-old HCM patient with MVO (*). Contrast-enhanced 4-chamber views in end-
ber views in end-diastole (E) and end-systole (F) in the same patient with MVO
nced 4-chamber views in end-diastole (G) and end-systole (H) showing apicalan
a 60-ye
ur-cham
t-enha
3.aneurysm formation in patients with MVO was more
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Midventricular Obstruction in HCM June 7, 2011:2346–55strongly associated with adverse outcomes. Our results
suggest that longer periods of exposure to MVO and
increased left ventricular wall stress might lead to apical
aneurysm formation and clinically unfavorable conse-
quences. The results also support the principle that the
presence of MVO in patients with HCM has important
pathophysiological implications. Timely recognition of
MVO might thus prompt changes in clinical practice to
allow for gradient relief and prophylactic defibrillator
implantation and could also guide the challenge of
improving the prognosis for HCM patients with MVO.
Further studies are required to determine the most
appropriate treatment strategies for patients with MVO.
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Baseline Characteristics of HCM Patients WithAccording to the Presence or Absenc of an ApTable 4 B selin Characteristics of HCM PaAccording to the Presence or Abse
P
a
Male
Age at diagnosis, yrs
Family history of sudden death
Maximum left ventricular wall thickness, mm
Nonsustained ventricular tachycardia
Atrial fibrillation
Unexplained syncope
NYHA functional class at diagnosis
I
II
III
IV
Progressive heart failure
Stroke
Pressure gradient at diagnosis, mm Hg
Treatments
Beta-blockers
Calcium-channel blockers
Class I antiarrhythmic drugs
All interventions combined
Warfarin
Follow-up duration, yrs
Values are n (%) or mean  SD.
Abbreviations as in Table 1.yuichiro24@celery.ocn.ne.jp.REFERENCES
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